drugset
drugset / Trial / NCT02448004

Study to Assess the Absorption, Metabolism and Excretion of 14C-JNJ-63623872 After a Single Dose in Healthy Male Participants

NCT02448004 ↗

Phase 1 Completed 6 enrolled Janssen Cilag N.V./S.A.
NaSingle-groupOpen-labelTreatment

Summary

The primary objective of this study is to characterize the absorption and metabolic pathways of JNJ-63623872, and the excretion of the compound and its metabolites, after single oral dosing of 14C-JNJ-63623872 in healthy adult male participants.

Timeline

Start
2015-05-11
Primary completion
2015-06-24
Completion
2015-06-24

Drugs

EvaluationDrugModalityDoseRoute
Subject Pimodivir Small molecule 600 mg Oral

Indications

No indication recorded.